REFERENCES
1. Xiao Z, and Theroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. 2004;43:1982-8.
2. Wakabayashi S, Kitahara H, Nishi T, Sugimoto K, Nakayama T, Fujimoto Y, et al. Platelet inhibition after loading dose of prasugrel in patients with ST-elevation and non-ST-elevation acute coronary syndrome. Cardiovascular intervention and therapeutics. 2018;33(3):239-46.
3. Lee S, Vargova K, Hizoh I, Horvath Z, Gulacsi-Bardos P, Sztupinszki Z, et al. High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy. 2014;133:257-64.
4. Pinxterhuis TH, Ploumen EH, Zocca P, Doggen CJM, Schotborgh CE, Anthonio RL, et al. Outcome after percutaneous coronary intervention with contemporary stents in patients with concomitant peripheral arterial disease: A patient-level pooled analysis of four randomized trials. Atherosclerosis.2022;355:52-9.
5. Khalid U, Bandeali S, Jones PG, Virani SS, Hira R, Hamzeh I, et al. Prescription Patterns of Clopidogrel, Prasugrel, and Ticagrelor After Percutaneous Coronary Intervention With Stent Implantation (from the NCDR PINNACLE Registry).Am J Cardiol. 2019;124(12):1807-12.
6. Sasaki M, Mitsutake Y, Ueno T, Fukami A, Sasaki KI, Yokoyama S, et al. Low ankle brachial index predicts poor outcomes including target lesion revascularization during the long-term follow up after drug-eluting stent implantation for coronary artery disease. J Cardiol. 2020;75(3):250-4.
7. Sidhu MS, Lyubarova R, Bangalore S, and Bonaca MP. Challenges of long-term dual antiplatelet therapy use following acute coronary syndromes. American heart journal.2022;246:44-64.
8. Bolognese L, and Angiolillo DJ. Unravelling the benefit against the risk of long-term dual antiplatelet therapy. Current opinion in cardiology. 2011;26 Suppl 1:S22-30.
9. Ryu SH, Park BY, Kim SY, Park SH, Jung HJ, Park M, et al. Regioselective hydroxylation of omeprazole enantiomers by bacterial CYP102A1 mutants. Drug metabolism and disposition: the biological fate of chemicals. 2014;42(9):1493-7.
10. Kang D, Geng T, Lian Y, Li Y, Ding G, Huang W, et al. Direct inhibition of Re Du Ning Injection and its active compounds on human liver cytochrome P450 enzymes by a cocktail method. Biomed Chromatogr. 2017;31(7).
11. Brosen K. Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland. Drug metabolism and personalized therapy. 2015;30(3):147-63.
12. Garcia C, Maurel-Ribes A, Nauze M, N’Guyen D, Martinez LO, Payrastre B, et al. Deciphering biased inverse agonism of cangrelor and ticagrelor at P2Y12 receptor.Cell Mol Life Sci. 2019;76(3):561-76.
13. Wu CC, Tsai FM, Chen ML, Wu S, Lee MC, Tsai TC, et al. Antipsychotic Drugs Inhibit Platelet Aggregation via P2Y 1 and P2Y 12 Receptors. Biomed Res Int.2016;2016:2532371.
14. Mwinyi J, Vokinger K, Jetter A, Breitenstein U, Hiller C, Kullak-Ublick GA, et al. Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy. Cancer chemotherapy and pharmacology.2014;73(6):1181-8.
15. Braun OO, Angiolillo DJ, Ferreiro JL, Jakubowski JA, Winters KJ, Effron MB, et al. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.Thrombosis and haemostasis. 2013;110(6):1223-31.
16. Xie X, Ma YT, Yang YN, Li XM, Ma X, Fu ZY, et al. CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population. PloS one. 2013;8(3):e59344.
17. Goh LL, Lim CW, Sim WC, Toh LX, and Leong KP. Analysis of Genetic Variation in CYP450 Genes for Clinical Implementation. PloS one. 2017;12(1):e0169233.
18. Barter ZE, Tucker GT, and Rowland-Yeo K. Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clinical pharmacokinetics. 2013;52(12):1085-100.
19. Huang X, Zhou Y, Zhang J, Xiang H, Mei H, Liu L, et al. The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients. British journal of clinical pharmacology. 2022.
20. Chambliss AB, Resnick M, Petrides AK, Clarke WA, and Marzinke MA. Rapid screening for targeted genetic variants via high-resolution melting curve analysis. Clin Chem Lab Med. 2017;55(4):507-16.
21. Yang L, George J, and Wang J. Deep Profiling of Cellular Heterogeneity by Emerging Single-Cell Proteomic Technologies. Proteomics. 2020;20(13):e1900226.
22. Jabir FA, and Hoidy WH. Pharmacogenetics as Personalized Medicine: Association Investigation of SOD2 rs4880, CYP2C19 rs4244285, and FCGR2A rs1801274 Polymorphisms in a Breast Cancer Population in Iraqi Women. Clin Breast Cancer.2018;18(5):e863-e8.
23. Mortarino M, Franceschi A, Mancianti F, Bazzocchi C, Genchi C, and Bandi C. [Quantitative PCR in the diagnosis of Leishmania]. Parassitologia.2004;46(1-2):163-7.
24. Bretagne S. Primary diagnostic approaches of invasive aspergillosis–molecular testing. Med Mycol. 2011;49 Suppl 1:S48-53.
25. Kwong KM, Tam CC, Chan R, Lee SWL, Ip P, and Kwok J. Comparison of Single Nucleotide Polymorphism genotyping of CYP2C19 by Loop-mediated isothermal amplification and real-time PCR melting curve analysis. Clin Chim Acta.2018;478:45-50.
26. Krajciova L, Petrovic R, Deziova L, Chandoga J, and Turcani P. Frequency of selected single nucleotide polymorphisms influencing the warfarin pharmacogenetics in Slovak population. Eur J Haematol. 2014;93(4):320-8.
27. Cooper JW. Adverse drug reaction-related hospitalizations of nursing facility patients: a 4-year study. South Med J. 1999;92(5):485-90.
28. Freitas AR, Tedim AP, Novais C, Lanza VF, and Peixe L. Comparative genomics of global optrA-carrying Enterococcus faecalis uncovers a common chromosomal hotspot for optrA acquisition within a diversity of core and accessory genomes.Microb Genom. 2020;6(6).
29. Zhang Y, Xu L, Qiu J, Li Z, Li L, Ren G, et al. Association between SNP rs10569304 on the second expressed region of hole gene and the congenital heart disease. J Huazhong Univ Sci Technolog Med Sci. 2010;30(4):430-6.